Group One Trading’s Candel Therapeutics CADL Stock Holding History

Group One Trading’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.3K	Buy	6,600 +3,200	+94%	+$17.4K	﹤0.01%	5603
2025 Q4	$19.2K	Sell	3,400 -7,900	-70%	-$42.5K	﹤0.01%	6363
2025 Q3	$57.6K	Sell	11,300 -8,200	-42%	-$47.4K	﹤0.01%	5835
2025 Q2	$98.7K	Sell	19,500 -23,000	-54%	-$118K	﹤0.01%	4978
2025 Q1	$240K	Buy	42,500 +35,500	+507%	+$290K	﹤0.01%	3832
2024 Q4	$60.8K	Buy	+7,000	New	+$41.4K	﹤0.01%	4910
2024 Q3	–	Sell	-600	Closed	-$3.72K	–	6689
2024 Q2	$3.72K	Buy	+600	New	+$4.5K	﹤0.01%	6068

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's CADL Position: Q1 2026 in Review

Group One Trading reduced its Candel Therapeutics (CADL) stake by 1.5% in Q1 2026, selling an estimated $735 and leaving 8,760 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5378.

Group One Trading first reported a position in CADL in Q4 2025 and has held it in 2 quarters since. The position peaked at $50.3K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Group One Trading held 8,760 shares of Candel Therapeutics worth $42.9K as of Q1 2026.
Group One Trading sold 135 Candel Therapeutics shares in Q1 2026, an estimated $735.
Candel Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5378 holding.
Group One Trading first reported a position in Candel Therapeutics in Q4 2025 and has held it in 2 quarters since.
Group One Trading's Candel Therapeutics position peaked at $50.3K in Q4 2025.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.